Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Opalka

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
British Journal of Haematology|March 1, 1993
Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemiaO Kloke, N Niederle, J Y Qiu, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical dataT Moritz, O Kloke, M Nagel-Hiemke, et al.
British Journal of Haematology|August 1, 1992
Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemiaU B Wandl, O Kloke, M Nagel-Hiemke, et al.
Cancer Research|June 13, 2000
Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expressionN S Werner, Z Siprashvili, L Y Fong, et al.
Genes, Chromosomes & Cancer|November 24, 1999
Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinomaL Wang, J Darling, J S Zhang, et al.
European Journal of Haematology|December 23, 2004
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myelomaP Schütt, P Ebeling, U Buttkereit, et al.
Genome Research|March 1, 1996
Construction of a consistent YAC contig for human chromosome region 3p14.1W Bardenheuer, S Michaelis, A Lux, et al.
Oncogene|March 21, 2000
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanomaS Ren, M J Smith, I D Louro, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
British Journal of Haematology|March 1, 1993
Impact of interferon alpha-induced cytogenetic improvement on survival in chronic myelogenous leukaemiaO Kloke, N Niederle, J Y Qiu, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1992
Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical dataT Moritz, O Kloke, M Nagel-Hiemke, et al.
British Journal of Haematology|August 1, 1992
Combination therapy with interferon alpha-2b plus low-dose interferon gamma in pretreated patients with Ph-positive chronic myelogenous leukaemiaU B Wandl, O Kloke, M Nagel-Hiemke, et al.
Cancer Research|June 13, 2000
Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expressionN S Werner, Z Siprashvili, L Y Fong, et al.
Genes, Chromosomes & Cancer|November 24, 1999
Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinomaL Wang, J Darling, J S Zhang, et al.
European Journal of Haematology|December 23, 2004
Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myelomaP Schütt, P Ebeling, U Buttkereit, et al.
Genome Research|March 1, 1996
Construction of a consistent YAC contig for human chromosome region 3p14.1W Bardenheuer, S Michaelis, A Lux, et al.
Oncogene|March 21, 2000
The p44S10 locus, encoding a subunit of the proteasome regulatory particle, is amplified during progression of cutaneous malignant melanomaS Ren, M J Smith, I D Louro, et al.
Pageof 7